Ishida F, Kamei T
Central Research Laboratories, Banyu Pharmaceutical Co. Ltd., Tokyo, Japan.
Mutat Res. 1987 Oct;180(2):231-7. doi: 10.1016/0027-5107(87)90219-3.
The mutagenic effects of etintidine (BL-5641), a novel histamine H2-receptor antagonist, was assessed using the chromosome aberration test in CHL cells and the micronucleus test in mice. (1) Etintidine did not show any chromosome aberrations in the presence or absence of S9 mix at any concentration tested. (2) Etintidine did not increase the frequency of micronuclei in polychromatic erythrocytes even at the dose of 50% of the LD50 at single (24 h) and chronological preparation after drug administration.
使用中国仓鼠肺(CHL)细胞染色体畸变试验和小鼠微核试验评估了新型组胺H2受体拮抗剂乙磺替丁(BL-5641)的致突变作用。(1)在任何测试浓度下,无论有无S9混合液,乙磺替丁均未显示出任何染色体畸变。(2)即使在单次给药(24小时)后以半数致死量(LD50)的50%剂量给药以及在药物给药后的连续制备中,乙磺替丁也未增加多染红细胞中的微核频率。